Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.75 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.75 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.75 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357058 | 0.91 | MAPK14 (0.67) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6159507 | 0.90 | MAPK14 (0.70) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL2354267 | 0.90 | MAPK14 (0.70) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL2356231 | 0.90 | MAPK14 (0.76) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6160775 | 0.89 | MAPK14 (0.74) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL14205909 | 0.89 | MAPK14 (0.74) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6159365 | 0.87 | MAPK14 (0.67) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL2358527 | 0.87 | MAPK14 (0.70) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL2355453 | 0.86 | MAPK14 (0.69) | MAPK14GAKLCKCYP3A4PDGFRB | |
| Ro-3201195 SCHEMBL4108597 | 0.86 | MAPK14 (1.00) | MAPK14GAKLCKCYP3A4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-6979693-B2 | Pyrazole derivatives-p38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | MAPK14 32/4885GAK 164/4885LCK 422/4885 |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885GAK 253/4885LCK 77/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885GAK 253/4885LCK 77/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | MAPK14 34/4885GAK 169/4885LCK 358/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | MAPK14 32/4885GAK 164/4885LCK 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.